Two Distinct Growth Paths: Johnson & Johnson vs AbbVie
Johnson & Johnson and AbbVie report strong Q1 2026 results, showcasing two contrasting growth paths as biosimilar cha...
Connect with industry professionals using effective methods. Discover ways to enhance your network and open new opportunities.
16,127 articlesJohnson & Johnson and AbbVie report strong Q1 2026 results, showcasing two contrasting growth paths as biosimilar cha...
As Zoom prepares for 2026, investors want to know how the company will grow revenue, expand margins, and win with AI....
BP's board removed Albert Manifold as chair and another director amid governance concerns raised to the board. The mo...
MicroStrategy, the world's largest corporate holder of Bitcoin, announced a major bond buyback this week, signaling a...
As markets digest AI hype, Synopsys faces a potential growth trap: strong licensing revenue amid squeezed margins and...
A decade-long income lure from QYLD masks a sizable NAV erosion. The ETF's NAV has declined about 35% since its 2013 ...
Realtracs signals a possible June 1 halt to Zillow's listing feed if Zillow doesn't meet updated IDX display rules by...
Curious about what the Agilent 2026 earnings call means for investors? This article breaks down the key takeaways, po...
CME Group is launching 24/7 Bitcoin futures and options, eliminating weekend gap signals and expanding around-the-clo...
A major hedge fund exit grabbed headlines as a fund controlled by William Oberndorf liquidated a sizable monday.com s...
Companies are ditching token-based performance dashboards as ROI from AI pivots to concrete business outcomes like re...
Mortgage REITs like AGNC regularly issue new shares to manage leverage and fund income opportunities. This article ex...